AntiViral Research Center In the Department of Medicine

Welcome to the AVRC

Innovation in HIV Research

The UC San Diego AntiViral Research Center (AVRC) develops and conducts innovative research that enhances the quality and duration of life for people living with or affected by HIV infection and other infections of global significance. The award-winning research center is an established leader in San Diego’s HIV research community and is well known for its HIV testing programs. Internationally, the AVRC extends its research and education programs to Africa, Asia, and South America.


ion theatre proudly announces a revival of the provocative Tony Award-winning "The Normal Heart" by Larry Kramer
Partners with San Diego service agencies to promote HIV/AIDS awareness and treatment
Novel Drug Combo Succeeds Against Multiple HCV Genotypes
No cases of virologic failure observed with ABT-493 plus ABT-530
Successful diagnosis of acute/early HIV infections may have contributed to fall in HIV incidence in San Diego
An HIV testing programme [The Early Test] targeting individuals with acute/early infection likely contributed to a decline in incident infections in San Diego after 2008, investigators report in Clinical Infectious Diseases.
An HIV Prevention Pill for Transgender Persons
UC launches first in the nation demonstration project
UC San Diego AVRC Hosts National HIV Scientists for 2015 Cure Conference
A collaborative HIV Cure Conference features presentations by researchers at the forefront of new cure advancements on June 16
‘Testing for Tickets’ Encourages HIV Testing, Offers Free LGBT Pride Festival Tickets
Innovative HIV testing campaign offers 250 free LGBT Pride Festival tickets to people who get tested starting June 15 and continuing until supplies run out
HIV Transmission Networks Mapped to Reduce Infection Rate
Susan Little, MD maps San Diego's HIV transmission network, identifies transmission "hot spots"
Treatment for HIV Should Start within Four Months of Infection
Study by AVRC researchers identifies optimum window for initiating antiretrovial therapy for CD-4+ T-cell recovery

External Resources: